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INVITED EXPERT REVIEWS

HVAD to HeartMate 3 Left Ventricular Assist
Device Exchange: Best Practices Recommendations
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Daniel Goldstein, MD, Diyar Saeed, MD, PhD, Jan Schmitto, MD, PhD,
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Mark S. Slaughter, MD, Evgenij Potapov, MD, Pavan Atluri, MD, Jennifer Cowger, MD, MS,
and Francis D. Pagani, MD, PhD, on behalf of the HeartWare HVAD System to HeartMate 3
Left Ventricular Assist System Device Exchange Advisory Group*
Section of Cardiac Surgery, University of Chicago, Chicago, Illinois; Heart Failure and Transplant Unit, St Vincent's
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The HeartWare HVAD System (Medtronic) is a durable implantable left ventricular assist device that has been implanted in
approximately 20,000 patients worldwide for bridge to transplant and destination therapy indications. In December 2020,
Medtronic issued an Urgent Medical Device Communication informing clinicians of a critical device malfunction in which
the HVAD may experience a delay or failure to restart after elective or accidental discontinuation of pump operation. Moreover, evolving retrospective comparative effectiveness studies of patients supported with the HVAD demonstrated a significantly higher risk of stroke and all-cause mortality when compared with a newer generation of a commercially available
durable left ventricular assist device. Considering the totality of this new information on HVAD performance and the availability of an alternate commercially available device, Medtronic halted the sale and distribution of the HVAD System in June
2021. The decision to remove the HVAD from commercial distribution now requires the use of the HeartMate 3 left ventricular assist system (Abbott, Inc) if a patient previously implanted with an HVAD requires a pump exchange. The goal of this
document is to review important differences in the design of the HVAD and HeartMate 3 that are relevant to the medical
management of patients supported with these devices, and to assess the technical aspects of an HVAD-to-HeartMate 3
exchange. This document provides the best available evidence that supports best practices.
(Ann Thorac Surg 2022;113:1770-7)
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T

he HeartWare HVAD System (Medtronic) is a

3 as the only commercially available device for primary

durable left ventricular assist device (LVAD)

implantation as well as for exchanging a previously

approved for bridge to transplant indication in

implanted HVAD (Figures 1 and 2). The goal of this

2012 and destination therapy indication in 2019, based

document is to (1) highlight differences in the design of

on data from the ADVANCE þ Continued Access Proto-

the HVAD and HeartMate 3 that are relevant to patient

col, ENDURANCE, and ENDURANCE Supplemental clin-

management; and (2) review the surgical management

ical studies.1-5 To date, the device has been implanted

of an HVAD-to-HeartMate 3 exchange. This document

in approximately 20,000 patients worldwide and had

provides the best available evidence and consensus

gained wide adoption, particularly in clinical scenarios

opinion that support best practices.

that use a left anterolateral thoracotomy approach for
device placement,6 for patients with smaller body size
and for off-label pediatric applications.7 In December
2020, Medtronic issued an Urgent Medical Device
Communication informing clinicians of a critical device
malfunction in which the HVAD System may experience
a delay or failure to restart after elective or accidental
discontinuation of pump operation.8 In addition,
mounting evidence from retrospective comparative
effectiveness

studies

demonstrated

a

signiﬁcantly

higher risk of stroke and all-cause mortality in HVAD recipients when compared with those receiving a newer
generation of a commercially available durable LVAD,
the HeartMate 3 left ventricular assist system (Abbott,
Inc).9-13 In a recent report, the HVAD was associated
with a higher incidence of major neurologic adverse
events in the late constant hazard phase (hazard ratio,
5.71)13 and higher risk of risk of mortality (hazard ratio,
3.20) compared with the HeartMate 3 device.9 Considering the totality of new information on HVAD performance, Medtronic halted its sale and distribution in
June 2021.
Understandably, numerous concerns and questions
have arisen from clinicians and patients. The most
pressing question is how to treat the patients who
remain supported with an HVAD. In particular, 2 options
have been advanced: (1) continue ongoing support with
the HVAD, only changing to a HeartMate 3 “for cause”
(ie, pump malfunction or infection); or (2) electively
perform an HVAD-to-HeartMate 3 exchange to reduce
the potential risk of patient harm that may occur from a
device malfunction related to the “failure to restart”
mode of device failure. Current recommendations from
Medtronic support the former strategy. Recent analyses
from The Society of Thoracic Surgeons Interagency
Registry for Mechanically Assisted Circulatory Support
registry has similarly supported a “for cause” approach
because continued support on a normally functioning
HVAD was associated with less risk than that associated
with exchange to a HeartMate 3.14 Furthermore, the
early risk of exchange from an HVAD-to-HeartMate 3
was similar to that of exchange from an HVAD-to-HVAD,

MATERIAL AND METHODS
DIFFERENCES IN DEVICE DESIGN AND IMPLICATIONS FOR
MEDICAL MANAGEMENT. Both pumps are continuous-

ﬂow LVADs with centrifugal ﬂow design.15,16 The HVAD
uses a hybrid engineering design to levitate the internal
impeller

with

passive

magnetic

levitation

and

a

hydrodynamic bearing. It incorporates an optional
proprietary pump speed management algorithm, termed
the “Lavare Cycle,”17 that is designed to reduce pump
and ventricular blood stasis and improve washout. The
HeartMate 3 is designed with complete magnetic
levitation of the internal impeller that permits greater
distances between the motor housing and the impeller
compared with the gaps that can be achieved with a
hydrodynamic bearing. Its pump operation includes an
obligatory change in pump speed that achieves a
reduction in ﬂow stagnation in the pump.18 Recent data
have suggested that the 2 pumps signiﬁcantly differ in
the rates of hemocompatibility-related adverse events,
particularly with respect to stroke.9-13 Whether these
dissimilarities are related to the differences in pump
design or their dynamic pump speed modulation
algorithms remains unknown.
Additional features of the HVAD include a real-time
display of pump waveforms on the HeartWare monitor
that depict the variability of blood ﬂow through the
pump and the ongoing collection of pump parameters
and performance data in the Controller logﬁles. Information gleaned from logﬁles, when used in combination
with clinical data and assessment, provides critical information on pump performance to support clinical decision making.19 The HeartMate 3 uses the HeartMate
Touch Communication System that provides clinicians
with the ability to wirelessly monitor the HeartMate 3
system, program system parameters such as pump
speed, assess and track alarm conditions, and view and
save performance data. The Touch Communication
System provides data on pump speed, pump power,
pump ﬂow, and pulsatility index.

suggesting that patients were not disadvantaged by

PATIENT MANAGEMENT. It is important to note that anti-

requiring an exchange to the HeartMate 3.14

coagulation, antiplatelet, and blood pressure (BP) man-

The decision to remove the HVAD from commercial
distribution now requires surgeons to use the HeartMate

agement recommendations for the HVAD System have
not been altered as a result of the HVAD device recall.
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than 81 mg daily. Initial aspirin dosing of 81 mg was

HeartWareTM
HVADTM System

HeartMate 3TM
Left Ventricular Assist System

associated with an increased risk of pump thrombosis and
stroke.20,21 In ENDURANCE, 29.7% of patients experienced a stroke with the HVAD device compared with
12.1% of patients receiving the comparator device, the
HeartMate II (Abbott Labs).4 In the ENDURANCE Supplemental clinical study, 14.7% of patients experienced a
stroke with the HVAD device compared with 12.1% of
patients with the HeartMate II device.5
Antithrombotic recommendations for the HeartMate 3

HVAD to HeartMate 3 Pump Exchange: Best Practices for
Surgical Management
FIGURE 1 With the removal of the HeartWare HVAD System (Med-

are based on the clinical experience from the MO Europe
enne
MENTUM 3 and HeartMate 3 Conformite
Mark clinical studies.22-25 It calls for warfarin anti-

tronic) from commercial distribution, the HeartMate 3 (Abbott, Inc)

coagulation with an international normalized ratio tar-

left ventricular assist system is now the only commercially available

geted to 2.0 to 3.0 and antiplatelet therapy with aspirin

durable left ventricular assist device to exchange for an HVAD in the

81 mg daily. In the MOMENTUM 3 clinical study, 9.9% of

event of a need to exchange an HVAD device.

patients receiving the HeartMate 3 experienced a stroke
compared with 19.4% receiving the HeartMate II.22 The

ANTICOAGULATION AND ANTIPLATELET MANAGEMENT.

safety of discontinuing aspirin therapy is currently being

Antithrombotic recommendations for the HVAD are based

evaluated in a multicenter, prospective, randomized,

on clinical experience in the ADVANCE þ Continued

double-blinded clinical trial.23

1,3

Access Protocol,

4

ENDURANCE,

and ENDURANCE

Supplemental clinical studies.5 Recommended antith-

BLOOD PRESSURE MANAGEMENT. BP management is

rombotic therapy included warfarin anticoagulation

important for both HVAD and HeartMate 3 devices

targeted to an international normalized ratio of 2.0 to

because continuous-ﬂow devices are afterload sensitive

3.0 as well as antiplatelet therapy with aspirin at more

and designed to optimally perform within a narrow

Pump Exchange of a HeartWareTM HVADTM to HeartMate 3TM Left
Ventricular Assist Device
?
Clinical Dilemma

Device Exchange Needed

June 3, 2021, Medtronic Inc. Stops
Distribution and Sale of the HeartWareTM
HVADTM System Due to Risk of
Neurological Adverse Events, Mortality
and Potential Failure to Restart.

Best Surgical Practices

• Exchange of the HVAD device
should be performed only “for
cause” e.g., pump malfunction.
• Assessment of the surgical risks
should determine surgical
approach and technique for the
exchange procedure.
• Remove all HVADTM device
components including sewing
ring and outflow graft when
feasible and safe.

HeartWareTM HVADTM
Left Ventricular Assist Device
HeartMate 3TM
Left Ventricular Assist Device

• Alternative approaches are
available including minimallyinvasive techniques.

FIGURE 2 Pump exchange of a HeartWare HVAD to HeartMate 3 LVAD. Exchange of the HVAD device should be performed only “for
cause,” for example, pump malfunction. The assessment of the surgical risks of the procedure should determine the surgical
approach and technique for the exchange procedure. Removal of all HVAD device components including sewing ring and outﬂow graft
is the optimal technique when feasible and safe. Alternative approaches are available, including minimally invasive techniques.
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range of BP. Data from the ENDURANCE Supplemental
clinical study demonstrated that an enhanced BP
protocol signiﬁcantly reduced mean arterial pressure
(MAP) and reduced the overall stroke rate by 24.2%,
with a 50% reduction in hemorrhagic strokes compared
with the original ENDURANCE clinical study in which
said protocol was absent.4,5 Current recommendations
for BP management for HVAD recipients include a
target MAP less than 85 mm Hg if the patient has a
palpable pulse or less than 90 mm Hg if the patient
does not have a palpable pulse.5,26 A manual cuff and
Doppler is the preferred method for measuring BP.
Conversely, BP management for patients supported
by the HeartMate 3 is less well deﬁned. Patients supported on the HeartMate 3 should be maintained with a
MAP between 80 and 90 mm Hg unless symptoms of
lightheadedness, poor organ perfusion, or other symptoms due to low pressure supervene, thereby mandating
a higher MAP goal. The risk of hemorrhagic stroke with
higher BP goals has not been deﬁnitively established as
with the HVAD. It is thought that the artiﬁcial pulse algorithm used in the HeartMate 3 may cause inaccuracies
in determination of MAP, causing clinicians to overestimate actual MAP27 (Table 1).
SURGICAL CONSIDERATIONS FOR LEFT VENTRICULAR
ASSIST DEVICE PUMP EXCHANGE. The global risk associ-

ated with LVAD exchange is often related to the preoperative status of the patient and is also driven by the reasons for
the exchange procedure. A recent systematic review estimated the risk of 30-day mortality for pump exchange in
the setting of changing devices was approximately 10%

TABLE 1

Medical Management: Best Practices

Recommendations

BP management
 BP management goals should be individualized to the patient’s
condition. Patients and caregivers should be trained to obtain BP
readings and record values before index hospital discharge and
should be provided speciﬁc MAP targets to notify their clinician for
possible intervention.
 For patients supported with an HVAD without a palpable pulse, a
manual cuff and Doppler is the preferred method for measuring BP
with a MAP targeting <90 mm Hg.
 For HVAD patients with a palpable pulse, MAP targets should be
<85 mm Hg.
 The target goals for BP management for patients supported with
the HeartMate 3 are not as well established as those for the HVAD.
Patients supported on the HeartMate 3 should be maintained with
a MAP between 80 and 90 mm Hg unless this BP goal is
associated with symptoms of lightheadedness, poor organ
perfusion, or other symptoms due to low pressure in which a
higher BP goal should be established. The risk of hemorrhagic
stroke with higher BP goals has not been deﬁnitively established
as with the HVAD.
Anticoagulation
 Patients supported on the HVAD and the HeartMate 3 should be
maintained on warfarin anticoagulation with a target international
normalized ratio of 2.0 to 3.0.
Antiplatelet therapy
 Patients supported on the HVAD should be maintained on
antiplatelet therapy with aspirin at a dose of >81 mg/d.
 Patients supported on the HeartMate 3 should be maintained on
antiplatelet therapy with aspirin 81 mg/d.
Device Management and Monitoring
 For the HVAD, clinicians should continue to monitor waveforms in
ambulatory and inpatient settings and use Autologs/HVADLogs to
better understand pump performance and to support clinical
decision making, including evaluation of suspected pump
thrombus, suction events, and so forth. The Autologs report
provides detailed information and trends regarding pump speed/
ﬂow/power, medium and high priority alarms, power source data,
and system setting changes.
 For the HeartMate 3, clinicians should continue to monitor pump
parameters on a routine basis to assess changes in pump
parameters.
 For both devices, it is important to assess the clinical condition of
the patient in addition to assessing pump parameters.

but varied by pump type.28 In addition to pump failure,
comorbidities may include right ventricular failure,

BP, blood pressure; MAP, mean arterial pressure.

hepatic or renal dysfunction, a history of prior stroke,
and ongoing hemolysis, coagulopathy, and platelet
dysfunction. All these comorbidities should be considered
when deciding on the operative method of exchange.
Preoperative medical management should include (1)
discontinuation of long-acting agents that may suppress
the sympathetic nervous system (eg, beta-blockers,
angiotensin receptor neprilysin inhibitor/angiotensinconverting enzyme inhibitor) to reduce risk of vasoplegia;
(2) optimization of right ventricular function with
inotropes, diuretics, or temporary mechanical support;
and (3) optimization of hemostatic function.
First, the appropriate position and angle of the HVAD

with transesophageal echocardiography guidance and
traction sutures placed from the pump to the chest wall
or adjusting the length of the outﬂow graft. Generous
dissection to free adhesions of the heart may be necessary to permit apical traction to optimize inﬂow cannula
alignment. Extending the pericardial incision, creating a
small preperitoneal space at the left ventricular apex, or
opening the left pleura may aid in accommodating the
larger HeartMate 3 pump housing to ensure proper
inﬂow cannula alignment.

inﬂow cannula must be determined using trans-

HVAD-TO-HEARTMATE 3 DEVICE EXCHANGE. There are

esophageal echocardiography or cross-sectional contrast

several important technical aspects of the exchange

study to assess inﬂow cannula position within the left

procedure to consider (Figure 3; Supplemental Figures 1-

ventricular chamber. If malposition of the inﬂow can-

3; Video 1). First is the difference in size and design of

nula is present, all components of the HVAD sewing ring

the apical connector/sewing ring between the 2 systems.

should be removed and the new HeartMate 3 sewing

Second is the discrepancy of the outﬂow graft diameter

ring should be attached to the apex. The inﬂow cannula

between the 2 systems. Third is the surgical approach for

position of the HeartMate 3 pump can then be optimized

device

exchange:

sternotomy

versus

anterolateral
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The HVAD sewing ring is constructed of titanium and

A

Photograph demonstrating differences in length of the cannula and
height of the pump housing.

Dacron polyester and secures the pump inﬂow cannula
in position with the aid of a torque wrench. The inner
portion of the metallic sewing ring is a C-clamp that can

TM

HeartMate 3

LVAD

HVAD

TM

System

be adjusted by turning a screw inside the clamp to
secure the base of pump’s inﬂow cannula for optimal
placement of the inﬂow cannula.
The HeartMate 3 device has 2 choices for apical connectors: a larger size sewing ring with metal housing to
maintain a ﬂat geometry of the felt sewing cuff and a
second, smaller design in which the metal housing has
been removed and the size of the felt sewing ring is
reduced in size (Supplemental Figure 5). The HeartMate
3 inﬂow cannula measures 22 mm in length from the

B

pump housing to cannula tip and 20 mm in external
Diagram providing pump weights and cannula lengths for the
HeartMate 3TM and HVADTM
INFLOW
HeartMate 3TM LVAD

diameter. The outer diameter of the inﬂow cannula for
the HeartMate 3 is smaller than that of the HVAD and
measures only 20.5 mm (this dimension includes the

Pump

Inflow

sintering surface) compared with 20.6 mm for the

Mass (or weight) = 200 g

Length = 22mm

outside diameter of the HVAD inﬂow cannula.15,16 Thus,

Volume = 80 mL

the inlet cannula of the HeartMate 3 cannot simply be
placed through the HVAD metallic sewing ring and

INFLOW

HVADTM System

obtain a hemostatic seal and requires deviations from

Pump

Inflow

the HeartMate 3 implant technique as developed in the

Mass (or weight) = 160 g

Length = 32.3mm

MOMENTUM 3 clinical study and described in the

Volume = 50 mL

HeartMate 3 Instructions for Use.29-31 Previous reports
have described use of a rubber seal to obtain hemostasis

FIGURE 3 Comparison of the pump dimensions and size for the HeartMate 3

at the inﬂow connection29,30 (Supplemental Figure 6).

and HeartWare HVAD System. (A) The differences in length of the cannula and

The long-term consequences of using an improvised seal

height of the pump housing. (B) The pump weights and cannula lengths for the

are unknown.

HeartMate 3 and HVAD. The diameter of the inﬂow cannula of the HVAD is
approximately 20.6 mm, and the diameter of the HeartMate 3 inﬂow cannula is

Outﬂow graft. The outﬂow grafts of the HVAD and

20.5 mm. The length of the sintering along the inﬂow cannula is approximately

HeartMate 3 differ in diameter, measuring 10 mm and

11.7 mm for the HVAD and approximately 22 mm for the HeartMate 3. The

14 mm, respectively (Supplemental Figure 7). This dif-

photographs are courtesy of Angela Lorts, MD, MBA, Cincinnati Children’s
Hospital Medical Center, Cincinnati, Ohio. (LVAD, left ventricular assist

ference in outﬂow graft diameter has important implications in the exchange procedure and recommendations

device.)

for best practices. During the exchange procedure, complete removal of the HVAD outﬂow graft would eliminate
the concern for discrepancy in outﬂow graft sizes. Suturthoracotomy. For surgeons with appropriate experience

ing of the HeartMate 3 outﬂow graft to a remnant of the

in alternative approaches, an anterolateral thoracotomy

HVAD outﬂow graft will necessitate a signiﬁcant reduc-

approach can be used to prevent injury to cardiac

tion in outﬂow graft diameter at the anastomosis or distal

structures or damage to the outﬂow graft if adherent to

to it. This reduction in size would increase afterload to the

the posterior sternal table.

HeartMate 332 (Supplemental Figure 8). The long-term

Apical sewing ring/connectors. The apical sewing ring

consequences of this increase in afterload to the Heart-

of the HVAD differs signiﬁcantly from that of the

Mate 3 are unknown and may potentially increase the risk

HeartMate 3 (Supplemental Figures 4 and 5). The

of hemocompatibility-related adverse events or result in

diameter, including the sewing cuff of the HVAD sewing

inadequate left ventricular unloading and manifestations

ring, measures 43 mm in size. The inﬂow cannula of the

of heart failure. In vitro studies suggest that suturing the

HVAD measures 25 mm from the “O” ring to cannula tip

14-mm outﬂow graft of the HeartMate 3 to varying lengths

and 32.3 mm from pump housing to cannula tip with a

of remnants of the HVAD 10-mm outﬂow graft increases

21-mm outer diameter. The HVAD pump is fabricated of

afterload to the HeartMate 3.32 Additional data suggest

smooth titanium with sintering halfway up and contains

that this added resistance may be overcome by adjust-

a silicone O-ring to ensure a seal with the sewing ring.

ment of pump speed.32 The unknown clinical conse-

The HVAD inﬂow cannula has a larger diameter

quences of higher rotor speeds on hemocompatibility

compared with the inﬂow cannula of the HeartMate 3.16

risks, battery runtime, and pump performance with
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TABLE 2

1775

Surgical Management: Best Practices Recommendations

other procedural considerations.
Exchange procedure. The technique for exchange that
is most consistent with the HeartMate 3 Instructions for
Use31 is to completely excise the preexisting HVAD
sewing ring and replace it with a new apical connector
speciﬁc to the HeartMate 3 device (Supplemental
Figure 9). Use of circulatory support with cardiopulmonary bypass or extracorporeal membrane oxygenation is recommended for the exchange procedure to
allow inspection of the left ventricular cavity and to
ensure that the pannus and left ventricular thrombus
are completely removed (Supplemental Figure 10). The
HeartMate 3 apical connector can then be sewn to the
left ventricular apex using a series of interrupted,
pledgetted, horizontal mattress sutures (w12 individ-

Indication for exchange
 Current data do not support “elective” HVAD-to-HeartMate 3 exchange to reduce the
potential risk of adverse events arising from a failure to restart device malfunction.11
Exchange from an HVAD-to-HeartMate 3 should be performed only “for cause” (ie, device
thrombosis or device electrical failure, or device infection not responsive to medical
management).
Technique for exchange
 Under optimal clinical scenarios, an HVAD-to-HeartMate 3 exchange should include removal
all components of the HVAD device and the apical sewing cuff of the HeartMate 3 device is
sewn to the apex of the left ventricle. The outﬂow graft of the HVAD System is completely
removed to reduce the discrepancy in outﬂow graft diameter between the 2 systems.
 It is both safe and feasible to implant a HeartMate 3 device through an anterolateral
thoracotomy approach. However, this technique does not address the issue of discrepancy
in size of the outﬂow graft between the 2 LVAD systems. An upper right anterior thoracotomy
or an upper hemi-sternotomy incision to tunnel the HeartMate 3 outﬂow graft through the
right chest to anastomose to the ascending aorta may be added to the anterolateral
thoracotomy approach for device exchange to exclude all remaining remnants of the HVAD
outﬂow graft. This technique must be balanced against using a remnant of the HVAD outﬂow
graft.
 Alternative approaches may be considered, if in the opinion of the surgical team, complete
excision of all HVAD components poses a unacceptable surgical risk.

ual sutures) for the standard cuff (Supplemental
Figure 11). Alternatively, 4 pledgetted sutures followed

LVAD, left ventricular assist device.

by a running polypropylene suture can be used to
obtain a secure attachment of the “mini” apical
connector to the left ventricular apex.
In addition to removal of the HVAD sewing ring,

excision and replacement of the existing HVAD sewing

complete removal of the outﬂow graft with enlargement

ring. Moreover, this technique reduces the depth of

of the aortotomy to accommodate the 14-mm outﬂow

insertion of the HeartMate 3 inﬂow cannula into the left

graft of the HeartMate 3 completely eliminates the

ventricular cavity, a conﬁguration with unknown

discrepancy in outﬂow graft size mismatch (Supple-

sequelae (ie, hemocompatibility-related adverse events).

mental Figure 12). This technique will prevent a pressure

Alternatively, the metal connector portion of the HVAD

drop across the reduced size HVAD outﬂow graft and

sewing ring can be removed while leaving only the fabric

avoid an increase in afterload to the HeartMate 3.

portion of the sewing ring. This technique can reduce

However, other procedural considerations must be

operative time and potentially have less effect on the

weighed, including the additional complexity of having

depth of insertion of the HeartMate 3 inﬂow cannula.

to clamp the ascending aorta partially or fully. Moreover,
the use a left anterolateral thoracotomy approach often

B. Implantation of the HeartMate 3 using the existing
apical sewing ring of the HVAD system

requires using a remnant of the HVAD outﬂow graft.33,34
Alternative surgical techniques for securing the Heart-

For the implantation of the HeartMate 3 inﬂow can-

Mate 3 to the left ventricular apex. Other options for

nula into the remaining HVAD metallic sewing ring, a

securing the HeartMate 3 to the left ventricular apex

sterile rubber seal can be placed around the inﬂow

have been advanced.29,30,33,34 Each has important po-

cannula of the HeartMate 3 to avoid leakage between

tential beneﬁts and limitations. If full sternotomy or

the HVAD metallic sewing ring and the inﬂow cannula of

complete replacement of the HVAD sewing ring with the

the HeartMate 329,30,33,34 (Supplemental Figure 6). The

HeartMate 3 apical connector poses unacceptable risk as

inﬂow cannula of the new HeartMate 3 can then be

assessed by the surgical team, the following modiﬁca-

placed into the established HVAD metallic sewing ring,

tions can be considered.29,30

and the screw of the HVAD sewing ring can be tightened.

A. Implantation of the HeartMate 3 by sewing the
HeartMate 3 apical connector over the existing
HVAD sewing ring
The HeartMate 3 sewing ring can be sewn to the left

The advantage of this technique is the reduction in the
time needed to replace the HVAD sewing ring and extent
of apical dissection. However, if a reliable seal is not
obtained, bleeding and potential for pseudoaneurysm
formation could occur.

ventricle over the existing HVAD sewing cuff. This is

Anterolateral left thoracotomy approach versus sternot-

feasible because the sewing ring of the HeartMate 3 is

omy

larger. This approach reduces surgical time because it

approach may offer several advantages to the redo-

obviates the amount of dissection needed to remove the

sternotomy approach for device exchange.33,34 In view

existing HVAD apical sewing ring. However, hemostasis

of the larger dimensions of the HeartMate 3, a wider

of this approach must be ensured and may be more

incision is generally required when using an antero-

technically difﬁcult to achieve compared with full

lateral thoracotomy approach.33 A major limitation of

approach. An

anterolateral

left

thoracotomy
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this approach is that a longer remnant of the HVAD
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CONCLUSIONS
This document outlines important differences that
exist in both patient management and techniques for
surgical exchange of an HVAD-to-HeartMate 3 exchange. Current data support the recommendation
that patients supported with a normally functioning
HVAD should remain on support and only undergo
exchange “for cause” because the risk of death due to
device exchange likely exceeds the risk of death
remaining on a normally functioning HVAD device. It
is likely that future analyses of data from registries of
durable LVAD devices will be performed to continue to
monitor evidence to support any changes to this
recommendation. Preferably, patients requiring an
HVAD-to-HeartMate
removal

of

all

3

exchange

HVAD

system

should

undergo

components

and

replacement with HeartMate 3 components unless, in
the opinion of the surgical team, this approach poses
unacceptable risk, in which case, alternative procedures that reduce the extent of dissection and reduce
surgical time can be used.
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